We aspire to surmount a universal problem for current and future targeted cancer therapies.
TOLREMO therapeutics' mission is to tackle non-oncogene addiction in cancer by blocking transcriptional escape pathways that operate parallel to the primary oncogene signaling axis. Leveraging our proprietary phenotypic screening platform, we have uncovered a novel role for CBP/p300 as an epigenetic master regulator of transcriptional resistance. Our clinical compound, TT125-802, is an orally available small molecule inhibitor of the bromodomain of CBP/p300 with a differentiated, best-in-class safety profile and activity as single agent in solid tumors. Targeting non-oncogene addiction represents a differentiated strategy to address a major challenge in cancer treatment, with significant therapeutic potential both as a monotherapy as well as in combination with targeted therapies in solid tumors and hematological malignancies.
Our Approach
We have discovered a key mechanism that governs transcriptional addiction in cancer.
Through a unique and novel approach to target identification and medicinal chemistry, we developed compounds capable of specifically blocking a critical mechanism upstream of transcriptional oncogene addiction - a key driver of cancer and drug resistance.
Our lead candidate TT125-802 provides a novel opportunity to block transcriptional addiction in cancer.
TT125-802 is an orally available, selective small molecule inhibitor that blocks the transcription of genes involved in primary and acquired resistance to targeted treatment.
Combining TT125-802 with targeted therapeutic agents for durable patient benefit
After a rapid dose escalation as monotherapy, we plan to advance TT125-802 with an innovative clinical development path that focuses on prevention of resistance by combining it with a range of targeted therapies. We will also continue to explore the astounding monotherapy activity of TT125-802 in non-small cell lung cancer.
We apply our expertise in transcriptional non-oncogene addiction to transform the cancer treatment landscape
With our team of experts in medicinal chemistry, bioinformatics and therapeutic development, we aim to deliver a novel therapeutic solution for transcriptional addiction for a broad range of targeted therapies.
Connect with us
Would you like to learn more about TOLREMO? Contact us at info@tolremo.com